These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

181 related articles for article (PubMed ID: 19403900)

  • 21. Relationship between antiretrovirals used as part of a cART regimen and CD4 cell count increases in patients with suppressed viremia.
    Mocroft A; Phillips AN; Ledergerber B; Katlama C; Chiesi A; Goebel FD; Knysz B; Antunes F; Reiss P; Lundgren JD
    AIDS; 2006 May; 20(8):1141-50. PubMed ID: 16691065
    [TBL] [Abstract][Full Text] [Related]  

  • 22. [Laboratory testing including CD4 T-cell count and determination of viral load to evaluate the impact of first line antiretroviral treatment at 6 months in adults in Benin].
    Ogouyemi-Hounto A; Zannou D; Metodakou D; Lafia B; Gomez V; Akinocho E
    Med Trop (Mars); 2010 Feb; 70(1):100. PubMed ID: 20337131
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Allocating antiretrovirals in South Africa: using modeling to determine treatment equity.
    Wilson DP; Blower SM
    PLoS Med; 2005 Jun; 2(6):e155; author reply e186. PubMed ID: 15971938
    [No Abstract]   [Full Text] [Related]  

  • 24. Patents versus patients? Antiretroviral therapy in India.
    Havlir DV; Hammer SM
    N Engl J Med; 2005 Aug; 353(8):749-51. PubMed ID: 16120852
    [No Abstract]   [Full Text] [Related]  

  • 25. [Nucleotide analog shows effectiveness in previously treated patients. The new kind of HAART].
    MMW Fortschr Med; 2002 Apr; 144 Suppl 1():62-4. PubMed ID: 12043078
    [No Abstract]   [Full Text] [Related]  

  • 26. Substituting tenofovir for stavudine in resource-limited settings: there are challenges ahead.
    van Griensven J; Lynen L; Colebunders R
    AIDS; 2009 May; 23(8):1027. PubMed ID: 19414993
    [No Abstract]   [Full Text] [Related]  

  • 27. Estimating the number of antiretroviral treatment facilities based on the Wilson-Blower method.
    Malangu N
    PLoS Med; 2005 Aug; 2(8):e270. PubMed ID: 16120012
    [No Abstract]   [Full Text] [Related]  

  • 28. CD4+ T cell evolution and predictors of its trend before and after tenofovir/didanosine backbone in the presence of sustained undetectable HIV plasma viral load.
    Torti C; Lapadula G; Barreiro P; Soriano V; Mandalia S; De Silvestri A; Suter F; Maggiolo F; Antinori A; Antonucci F; Maserati R; El Hamad I; Pierotti P; Sighinolfi L; Migliorino G; Ladisa N; Carosi G;
    J Antimicrob Chemother; 2007 Jun; 59(6):1141-7. PubMed ID: 17434879
    [TBL] [Abstract][Full Text] [Related]  

  • 29. [Antiretroviral therapy in 2004].
    Jablonowski H
    MMW Fortschr Med; 2004 Apr; 146 Spec No 1():46-8, 50-1. PubMed ID: 15373049
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Rational choices for allocating antiretrovirals in Africa: treatment equity, epidemiological efficiency, and feasibility.
    Wilson DP; Blower SM
    PLoS Med; 2006 Mar; 3(3):e160. PubMed ID: 16563042
    [No Abstract]   [Full Text] [Related]  

  • 31. Meeting notes from ICAAC. Tenofovir + emtricitabine vs. AZT + 3TC.
    Feinberg J
    AIDS Clin Care; 2005 Jan; 17(1):7. PubMed ID: 15717373
    [No Abstract]   [Full Text] [Related]  

  • 32. In resource-limited settings good early outcomes can be achieved in children using adult fixed-dose combination antiretroviral therapy.
    O'Brien DP; Sauvageot D; Zachariah R; Humblet P;
    AIDS; 2006 Oct; 20(15):1955-60. PubMed ID: 16988517
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Registration problems for antiretrovirals in Africa.
    Ford N; Darder M
    Lancet; 2006 Mar; 367(9513):794-5. PubMed ID: 16530559
    [No Abstract]   [Full Text] [Related]  

  • 34. [One year with Atripla. Changeover to complete HIV therapy in a single tablet has proven successful].
    Warpakowski A
    MMW Fortschr Med; 2009 Apr; 151(18):54-5. PubMed ID: 19769077
    [No Abstract]   [Full Text] [Related]  

  • 35. Comment on: suboptimal CD4 gains in HIV-infected patients receiving didanosine plus tenofovir.
    Anderson PL; Kakuda TN
    J Antimicrob Chemother; 2006 Jul; 58(1):220-1. PubMed ID: 16717052
    [No Abstract]   [Full Text] [Related]  

  • 36. [HIV and AIDS: what's new in 2010?].
    Calmy A; Schiffer V; Hirschel B
    Rev Med Suisse; 2011 Jan; 7(278):159-63. PubMed ID: 21400951
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Tenofovir DF on the horizon. Investigational nucleotide reverse transcriptor inhibitor could be on pharmacy shelves soon.
    Eagan L
    Posit Living; 2001; 10(5):21. PubMed ID: 11693102
    [No Abstract]   [Full Text] [Related]  

  • 38. Antiretroviral treatment. HIV infection in adults: better-defined first-line treatment.
    Prescrire Int; 2004 Aug; 13(72):144-50. PubMed ID: 15532140
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Combining evidence for access to and benefits from antiretroviral treatment to inform planning.
    ; Marlink R; Forsythe S; Bertozzi SM; Muirhead D; Holmes M; Sturchio J
    AIDS; 2008 Jul; 22 Suppl 1():S121-2. PubMed ID: 18664943
    [No Abstract]   [Full Text] [Related]  

  • 40. [HIV therapy: tenofir DF is available in 68 developing countries at production costs price].
    Med Klin (Munich); 2003 Jul; 98(7):XV-XVI. PubMed ID: 12945544
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.